We are live on
!
Find out more
Marsico Capital Management Portfolio holdings
AUM
$3.83B
Turnover
32.5%
1-Year Est. Return
63.68%
This Fund
S&P 500
This Quarter
Est. Return
+3.08%
1 Year Est. Return
+63.68%
3 Year Est. Return
+288.07%
5 Year Est. Return
+405.68%
10 Year Est. Return
+2,460.26%
AUM
$11.3B
AUM Growth
-$536M
(-4.5%)
Cap. Flow
-$722M
Cap. Flow
% of AUM
-6.38%
Top 10 Holdings %
Top 10 Hldgs %
44.21%
Holding
104
New
17
Increased
29
Reduced
44
Closed
13
Avg Time Held
0.9
years
Top 10 Avg Time Held
0.8
years
Top 20 Avg Time Held
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Illumina
ILMN
|
+$232M |
| 2 |
Electronic Arts
EA
|
+$162M |
| 3 |
Salesforce
CRM
|
+$118M |
| 4 |
Bausch Health
BHC
|
+$90.4M |
| 5 |
Zoetis
ZTS
|
+$87.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$265M |
| 2 |
Biogen
BIIB
|
+$215M |
| 3 |
Canadian Pacific Kansas City
CP
|
+$190M |
| 4 |
Union Pacific
UNP
|
+$158M |
| 5 |
Alibaba
BABA
|
+$148M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 29.77% |
| 2 | Communication Services | 19.78% |
| 3 | Technology | 14.98% |
| 4 | Consumer Discretionary | 12.47% |
| 5 | Financials | 7.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Apple
AAPL
$5.01T
| $810M | 7.16% |
25,840,720
+1,915,872
| +8% | +$61.3M |
2014 Q2
4 quarters
|
|
2
Meta Platforms (Facebook)
META
$1.88T
| $764M | 6.75% |
8,905,682
-442,313
| -5% | -$36.1M |
2013 Q3
7 quarters
|
|
3
Walt Disney
DIS
$188B
| $611M | 5.4% |
5,355,096
-97,092
| -2% | -$10.7M |
2013 Q2
8 quarters
|
|
|
4
Biogen
BIIB
$34.4B
| $518M | 4.58% |
1,282,348
-536,523
| -29% | -$215M |
2013 Q2
8 quarters
|
|
5
Visa
V
$735B
| $451M | 3.99% |
6,720,582
-696,481
| -9% | -$47.2M |
2013 Q2
8 quarters
|
|
|
AGN
6
DELISTED
Allergan plc
AGN
| $441M | 3.9% |
1,453,317
-164,593
| -10% | -$49.1M |
2014 Q4
2 quarters
|
|
7
UnitedHealth
UNH
$355B
| $361M | 3.19% |
2,962,836
-33,997
| -1% | -$4.02M |
2014 Q4
2 quarters
|
|
8
HCA Healthcare
HCA
$102B
| $355M | 3.14% |
3,914,467
-17,755
| -0.5% | -$1.42M |
2014 Q3
3 quarters
|
|
9
Dollar Tree
DLTR
$22.8B
| $346M | 3.06% |
4,384,058
-57,696
| -1% | -$4.56M |
2015 Q1
1 quarter
|
|
10
Sherwin-Williams
SHW
$78.8B
| $346M | 3.06% |
3,776,094
-264,195
| -7% | -$25M |
2013 Q2
8 quarters
|
|
11
Nike
NKE
$52.4B
| $329M | 2.9% |
6,086,030
-296,086
| -5% | -$15.2M |
2014 Q3
3 quarters
|
|
|
12
Illumina
ILMN
$41B
| $323M | 2.85% |
1,520,242
+1,188,183
| +358% | +$232M |
2015 Q1
1 quarter
|
|
|
13
DELISTED
Electronic Arts
EA
| $304M | 2.69% |
4,578,475
+2,639,659
| +136% | +$162M |
2014 Q4
2 quarters
|
|
14
Boeing
BA
$146B
| $286M | 2.53% |
2,064,418
+285,379
| +16% | +$41.6M |
2015 Q1
1 quarter
|
|
15
Charles Schwab
SCHW
$167B
| $284M | 2.51% |
8,703,510
+279,634
| +3% | +$8.84M |
2014 Q1
5 quarters
|
|
16
ASML
ASML
$634B
| $280M | 2.47% |
2,689,884
+8,086
| +0.3% | +$864K |
2013 Q2
8 quarters
|
|
17
Starbucks
SBUX
$106B
| $278M | 2.46% |
5,186,886
-127,552
| -2% | -$6.47M |
2013 Q2
8 quarters
|
|
18
Vertex Pharmaceuticals
VRTX
$126B
| $241M | 2.13% |
1,950,563
-209,553
| -10% | -$26.4M |
2015 Q1
1 quarter
|
|
|
LNKD
19
DELISTED
LinkedIn Corporation
LNKD
| $231M | 2.04% |
1,118,362
+381,522
| +52% | +$85M |
2013 Q3
7 quarters
|
|
|
20
Canadian Pacific Kansas City
CP
$75.7B
| $231M | 2.04% |
7,208,350
-5,314,770
| -42% | -$190M |
2013 Q2
8 quarters
|
|
|
21
Bausch Health
BHC
$2.2B
| $209M | 1.85% |
940,723
+407,776
| +77% | +$90.4M |
2015 Q1
1 quarter
|
|
|
22
Salesforce
CRM
$194B
| $209M | 1.84% |
2,997,569
+1,657,747
| +124% | +$118M |
2013 Q2
8 quarters
|
|
23
Comcast
CMCSA
$74.7B
| $192M | 1.7% |
6,384,260
-1,885,152
| -23% | -$55.3M |
2013 Q2
8 quarters
|
|
|
CELG
24
DELISTED
Celgene Corp
CELG
| $179M | 1.59% |
1,550,832
-497,504
| -24% | -$56.9M |
2013 Q2
8 quarters
|
|
|
25
Alibaba
BABA
$277B
| $178M | 1.57% |
2,160,325
-1,717,847
| -44% | -$148M |
2014 Q3
3 quarters
|
|
Similar funds
Marsico Capital Management's Q2 2015 Portfolio in Review
As of Q2 2015, Marsico Capital Management held 104 positions worth $11.3B, down 4.5% from $11.9B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Marsico Capital Management withdrew a net $722M in Q2 2015, closing 13 positions and reducing 44 holdings. Its most notable exit was Gilead Sciences, an estimated $265M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 30% a quarter earlier, followed by Communication Services and Technology.
Against the trend, Marsico Capital Management opened a new position in Zoetis worth $88.2M.
- Marsico Capital Management's largest Q2 2015 buy was Zoetis: 1,828,140 shares worth $88.2M.
- Marsico Capital Management added most to Illumina in Q2 2015, an estimated $232M increase.
- Marsico Capital Management's biggest Q2 2015 reduction was Biogen, cutting an estimated $215M.
- Marsico Capital Management fully exited Gilead Sciences in Q2 2015, selling an estimated $265M.
- Marsico Capital Management's ten largest holdings make up 44% of its $11.3B portfolio in Q2 2015.
- Marsico Capital Management opened 17 new positions and closed 13 in Q2 2015.
- Marsico Capital Management's portfolio value fell 4.5% quarter-over-quarter to $11.3B.
Based on Marsico Capital Management's 13F filing for Q2 2015, filed 13 Aug 2015.